SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Poly Medicure Ltd (POLYMED)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531768 NSE: POLYMED Medical Equipment/Supplies/Accessories | Small Cap | Poly Medicure Share Price

₹1,737.80 72.85 (4.38%)

As on 02-Jul'26 16:59

Poly Medicure Ltd (POLYMED)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531768 NSE: POLYMED Medical Equipment/Supplies/Accessories | Small Cap | Poly Medicure Share Price

₹1,737.80 72.85 (4.38%)

As on 02-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹17,614 Cr.
Current Price
₹1,737.8
52-Week Low / High
₹1,184 / 2,318
TTM EPS
₹33.2
TTM Sales
₹1,662 Cr.
Book Value per Share
₹301.2
P/E Ratio
52.43
Lower than its 5-year historical median
Industry PE
112.3
Price to Book (P/B)
5.77
Lower than its 5-year historical median
Price to Sales (P/S)
10.60
Lower than its 5-year historical median
EV/EBITDA
31.48
Lower than its 5-year historical median
Dividend Yield
0.2%
Profitability Efficiency
Return on Equity (ROE)
15.79%
In line with industry median
Return on Capital Employed (ROCE)
20.14%
In line with industry median
Return on Assets (ROA)
12.94%
Operating Profit Margin
27.9%
Net Profit Margin
20.69%
Gross Profit Margin
32.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
22.53%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
27.43%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
31.63%
Asset Quality
Promoter Holding
62.42%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹3,002 Cr.
Equity
₹50.7 Cr.
Face Value
₹5
All Time Low / High
₹0.50 / 3350.00

Poly Medicure stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Poly Medicure Ltd a good quality company?
Poly Medicure Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Poly Medicure Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Poly Medicure Ltd vs industry peers?
Poly Medicure Ltd revenue CAGR is 19.91%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Poly Medicure Ltd?
Promoters hold 62.42% of the Poly Medicure Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Poly Medicure Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 24.8% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Poly Medicure Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 26.1%25.3%26%22.9%24.6%21.6%17.7%19.3%23.3%20.1%-
Value Creation
Index
0.90.80.90.60.80.60.30.40.70.8-

Growth Parameters

Sales 3944405085876467478791,0681,3071,6021,662
Sales YoY Gr.-11.4%15.7%15.4%10.1%15.7%17.7%21.5%22.4%22.5%-
Adj EPS 55.67.16.99.612.914.317.92531.233.2
YoY Gr.-12.4%27.1%-3.1%39.4%34%10.7%25.6%39.6%24.6%-
BVPS (₹) 25.430.537.94348.699.4112.1128.4151.6270.6301.2
Adj Net
Profit
4449.562.960.985124137172240316336
Cash Flow from Ops. 61.95575.5113127116126197256237-
Debt/CF from Ops. 1.31.81.71.31.51.10.90.70.60.7-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 16.9%19.9%22.1%22.5%
Adj EPS 22.6%26.5%29.8%24.6%
BVPS30.1%41%34.1%78.5%
Share Price 24.4% 11.6% 14.8% -22.5%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
21.220.120.817.12117.913.514.917.81511.6
Op. Profit
Mgn %
21.921.423.922.825.128.224.325.326.927.926.8
Net Profit
Mgn %
11.211.312.410.413.216.515.616.118.419.720.2
Debt to
Equity
0.40.40.40.40.40.10.10.10.10.10
Working Cap
Days
144146157159173182177173167165182
Cash Conv.
Cycle
67758080787889928793136

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3944395085876467478791,0681,3071,602
Operating Expenses + 3083453874534845376658029561,154
Manufacturing Costs100113131143153162200243276337
Material Costs107110121152153197261300364424
Employee Cost 698194110127131150188229280
Other Costs 334141485147547088113
Operating Profit 8694122134162210214266351447
Operating Profit Margin (%) 21.9%21.4%23.9%22.8%25.1%28.1%24.3%24.9%26.9%27.9%
Other Income + 8141416191939365890
Exceptional Items 0000000000
Interest 108111320105101314
Depreciation 20232836394653566281
Profit Before Tax 657696100122173195237335443
Tax 182026342944495883112
Profit After Tax 4756706692130146179252331
PAT Margin (%) 12.0%12.8%13.8%11.3%14.3%17.3%16.6%16.8%19.3%20.7%
Adjusted EPS (₹)5.46.48.07.510.513.515.218.726.232.7
Dividend Payout Ratio (%)28%39.30%25.10%26.60%19.10%18.50%16.40%16.10%11.40%10.70%

Valuation of Poly Medicure - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 2242693343794299531,0751,2321,4552,742
Share Capital 22444444444848484851
Reserves 2022252903353859051,0271,1841,4072,691
Debt +61761061271559181112146167
Long Term Debt3148799111160311210
Short Term Debt30282735443150101145167
Minority Interest0000000000
Trade Payables30414350605678788977
Others Liabilities 616371105128131100173204242
Total Liabilities 3764495556617721,2311,3341,5961,8943,228

Fixed Assets

Net Fixed Assets +1772002562693243854475978311,047
Gross Block2883334174615506557649631,2551,536
Accumulated Depreciation111133161192226270317365424489
CWIP 14201819252143787193
Investments 661842583853841812211,127
Inventories41586974101109150183193250
Trade Receivables8195112124120149191221259340
Cash Equivalents 2122205322278171137143
Others Assets 37476180122154110165183227
Total Assets 3764495556617721,2311,3341,5961,8943,228

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 625575113127116126197256237
PBT 657696100122173195237335443
Adjustment 25223841504539603636
Changes in Working Capital -14-25-36-1-10-58-60-42-41-154
Tax Paid -14-18-23-27-36-44-47-58-74-89
Cash Flow From Investing Activity + -30-54-87-104-106-434-89-189-237-1,191
Capex -31-55-81-45-104-93-150-237-269-324
Net Investments -1-2-8-62-7-344574820-882
Others 232353401215
Cash Flow From Financing Activity + -31-114-10-22319-40-8-17953
Net Proceeds from Shares 000004000001,000
Net Proceeds from Borrowing 0000000000
Interest Paid -8-7-9-12-9-8-4-8-10-11
Dividend Paid -27-13-5-21-420-24-24-29-30
Others 419292330-73-122422-6
Net Cash Flow 103-1-11-2-02-2

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)22.7522.8123.2818.5822.8518.7414.415.5218.7415.79
ROCE (%)26.1425.325.9622.9224.6421.6217.6819.3423.2820.14
Asset Turnover Ratio1.11.081.020.970.910.750.690.730.750.63
PAT to CFO Conversion(x)1.320.981.071.711.380.890.861.11.020.72
Working Capital Days
Receivable Days647274.207368.8065.4070.3070.2066.8068
Inventory Days43.1040.3045.3044.1049.2051.1053.6056.7052.3050.20
Payable Days115.60117.30126.80111.50131.40107.8093.6094.8083.9071.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Poly Medicure Ltd FAQs

The current trading price of Poly Medicure on 02-Jul-2026 16:59 is ₹1,737.8.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Poly Medicure stood at ₹17,614.3 Cr

The latest P/E ratio of Poly Medicure as of 01-Jul-2026 is 52.43.

The latest P/B ratio of Poly Medicure as of 01-Jul-2026 is 5.77.

The 52-week high of Poly Medicure is ₹2,318.4 and the 52-week low is ₹1,184.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Poly Medicure is ₹1,662 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Poly Medicure Ltd is a good quality company.

The key valuation ratios of Poly Medicure Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Poly Medicure Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Poly Medicure Ltd

Poly Medicure Ltd. was conceived and established by a group of engineers and technocrats dedicated to the idea of providing the benefits of modern healthcare to the mankind at affordable price. This unique philosophy has been the driving force behind the company since its inception in 1995. Today it has grown into one of the most dynamically versatile manufacturers of disposable healthcare products in the region with over 60 different products.

POLYMED manufactures its products using state of the art technology in ultra modern facilities covering over 300,000 square feet of manufacturing floor space with about 50,000 square feet of clean rooms of class 100,000 to class 1,000. A tool room with modern facilities & CNC machines supports the manufacturing processes. A high degree of automation and an effective process control helps in delivering consistent product quality.

To keep pace with the ever changing requirements of the market, POLYMED has a fully staffed and highly equipped R & D section to design and develop new and innovative products. Using the latest CAD/CAM technology, the new product development is fast and improvements, based on market response and customer feedback, are made with ease. Assuring world class products at affordable prices is the hall mark of POLYMED

Product range of the company:

The company manufactures different products related to :

  • Infusion Therapy
  • Central Venous Access Catheters
  • Anaesthesia
  • Urology
  • Gastroenterology
  • Blood Management
  • Surgery & Wound Drainage
  • Dialysis
  • Others

Achievements/ recognition:

  • QMS (Quality Management System) accredited by SGS
  • ISO 9001:2000
  • ISO-13485:2003
  • CE mark from DNV
  • US FDA 510k approved  
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: